Tyrosine kinase receptor expression in thymomas
- 124 Downloads
Promising new therapies for neoplasia include tyrosine kinase receptor antagonists. Tyrosine kinase oncogenes present an appealing anti-tumor drug target since they play an integral role in a variety of cellular responses including cell proliferation and differentiation. We previously demonstrated a high rate of epidermal growth factor receptor (EGFR) expression in advanced-stage thymic epithelial tumors. More recently, we have examined c-KIT (CD117) expression in a similar series of tumors.
Tumor from 35 patients seen at our institution for treatment of advanced-stage thymoma was available. Twenty thymomas and 15 thymic carcinomas were assessed for c-KIT expression. Tissue sections of tumor were stained immunohistochemically with anti-c-KIT (Oncogene). Either cytoplasmic or membrane staining was considered positive. Appropriate controls were performed. Positive staining for c-KIT was present in 12 tumors (11 thymic carcinomas and 1 thymoma).
In distinction to EGFR, c-KIT is expressed more commonly in thymic carcinomas (73% of carcinomas) than in thymoma (5% of thymomas).
An EGFR negative/c-KIT positive staining pattern is typical of thymic carcinoma, whereas thymomas are generally EGFR positive/c-KIT negative. Possible therapeutic implications of these observations remain to be determined.
Keywordsc-KIT CD 117 Tyrosine kinase Thymoma Thymic carcinoma
We thank Ms. C. Dodson and Mrs. L. Baldridge for their technical expertise and assistance with immunohistochemical staining.
- Bonner JA, Ezekiel MP, Robert F et al. (2000) Continued response following treatment with IMC-C225, an EGFr MoAb, combined with RT in advanced head and neck malignancies [abstr]. ASCO Program/Proceedings 19:5F. Available from URL: http://www.asco.org/prof/me/html/00abstracts/p/m_5F.htm (accessed 8 November 2000)Google Scholar
- Gibson PC, Cooper K (2002) CD117 (KIT): a diverse protein with selective applications in surgical pathology. Adv Anat Pathol 9:65–69Google Scholar
- Henley JD, Koukoulis GK, Loehrer PJ Sr (2002) Epidermal growth factor receptor expression in invasive thymoma. J Cancer Res Clin Oncol 128:167–170Google Scholar
- Levine GD, Rosai J (1978) Thymic hyperplasia and neoplasia: a review of current concepts. Human Pathol 9:495–515Google Scholar
- Marino M, Muller-Hermelink HK (1985) Thymoma and thymic carcinoma. Relation of thymoma epithelial cells to the cortical and medullary differentiation of thymus. Virchows Arch [A] 407:119Google Scholar
- Pescarmona E, Pisacane A, Pignatelli E et al. (1993) Expression of epidermal and nerve growth factor receptors in human thymus and thymomas. Histopathology. 23:39–44Google Scholar
- Rubin MS, Shin DM, Pasmantier M et al. (2000) Monoclonal antibody (MoAb) IMC-C225, an anti-epidermal growth factor receptor (EGFr), for patients (Pts) with EGFr-positive tumors refractory to or in relapse from previous therapeutic regimens [abstr]. ASCO Program/Proceedings 19:1860. Available from URL: http://www.asco.org/prof/me/html/00abstracts/ibt/m_1860.htm (accessed 8 November 2000)Google Scholar
- Veale D, Ashcroft T, Marsh C et al. (1987) Epidermal growth factor receptors in non-small cell lung cancer. Br J Cancer. 55:513–516Google Scholar
- Yang XD, Jia XC, Corvalan JRF et al. (2000) Therapeutic potential of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer treatment. ASCO Program/Proceedings 19:183. Available from URL: http://www.asco.org/prof/me/html/00abstracts/bmt/m_183.htm (accessed 8 November 2000)Google Scholar
- Yang XD, Jia XC, Corvalan JRF et al. (1999) Potent anti-tumor activity of ABX-EGF, a fully human monoclonal antibody to the epidermal growth factor receptor. ASCO Program/Proceedings 18:1766. Available from URL: http://www.asco.org/prof/me/html/00abstracts/bmt/m_183.htm (accessed 8 November 2000)Google Scholar